Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-05 for Agitation in Alzheimer's Disease
NCT04797715Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Dec 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing AXS-05 with Placebo (2 arms). Primary endpoint: Time from randomization to relapse of agitation symptoms up to 26 weeks. Started Dec 2020; status: completed.
02
Drugs
dextromethorphan + bupropion
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04797715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797715.